PPD and Taijitu form MAb discovery JV
PPD and Taijitu Biologics have launched a new joint venture to help drugmakers develop the next generation of monoclonal antibody (MAb) drugs.
PPD and Taijitu Biologics have launched a new joint venture to help drugmakers develop the next generation of monoclonal antibody (MAb) drugs.
Aurobindo Pharma is to sell its Chinese unit to Sinopharm as part of a strategic shift from low-margin ingredients to more profitable formulations.
Advances in materials technology are driving the autoinjection drug delivery device market according to new research.